Last week, Senator Claire McCaskill, D-Missouri, together with the minority staff of the Senate Homeland Security and Government Affairs Committee (HSGAC), released a report on prescription drug price increases that affect the 20 products most commonly prescribed to seniors.
Last week, Senator Claire McCaskill, D-Missouri, together with the minority staff of the Senate Homeland Security and Government Affairs Committee (HSGAC), released a report on prescription drug price increases that affect the 20 products most commonly prescribed to seniors.
According to the report, which used data from CMS and the IQVIA National Sales Perspectives information service, prices increased over the last 5 years for all 20 drugs in question, which include the diabetes medications insulin glargine (Lantus) and insulin aspart (NovoLog).
On average, prices for these drugs increased by 12% every year for the past 5 years, a rate that is approximately 10 times higher than the average annual rate of inflation. The percent change in price between 2012 and 2017 ranged from a low of 31% (for the shingles vaccine Zostavax) to a high of 477% (for the brand-name nitroglycerin, Nitrostat).
According to the report, these continual increases in price are keeping healthcare costs high despite reduced use of many of these drugs; while prescriptions rose for treatments including the blood-thinner rivaroxaban (Xarelto) and the dry-eye drug cyclosporine (Restasis), many of the 20 most-prescribed drugs saw sharp declines in prescribing from 2012 to 2017; prescriptions for rosuvastatin (Crestor) dropped by 94%, and nitroglycerine by 93%, for example.
“These findings underscore the need for further investigation by the Committee and other policymakers into dramatic price spikes and their impact on healthcare system costs and financial burdens for the growing US senior population,” conclude the authors.
In a statement, McCaskill added, “Can you imagine if you went to an auto dealership and last year’s exact model was being sold at a [20%] mark-up, and then you went back the next year and it had happened again? That’s exactly what’s happening in the prescription drug industry, where the cost of identical drugs skyrockets year after year.”
Juliet Johnson, a representative of the Pharmaceutical Research and Manufacturers of America (PhRMA) told CNN that the document is “yet another misleading report that ignores the robust negotiation that occurs between Medicare Part D plans, middlemen and biopharmaceutical companies.” Johnson added that PhRMA agrees that “…more can be done to make Part D more affordable and predictable for seniors. One way to do that is to ensure seniors benefit from the significant negotiated savings when they pick up their medicine at the pharmacy.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.